These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 11359971)

  • 1. Pneumococcal conjugate vaccine--relevance for developing countries.
    Mulholland K
    Indian Pediatr; 2001 May; 38(5):453-60. PubMed ID: 11359971
    [No Abstract]   [Full Text] [Related]  

  • 2. Impact of infant immunization programs with pneumococcal conjugate vaccine in Europe.
    Rose M; Zielen S
    Expert Rev Vaccines; 2009 Oct; 8(10):1351-64. PubMed ID: 19803758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A 10-valent conjugate vaccine for some countries.
    Prescrire Int; 2011 Jan; 20(112):8. PubMed ID: 21462783
    [No Abstract]   [Full Text] [Related]  

  • 4. Pneumococcal vaccination for Indian children.
    Levine OS; Cherian T
    Indian Pediatr; 2007 Jul; 44(7):491-6. PubMed ID: 17684301
    [No Abstract]   [Full Text] [Related]  

  • 5. Prevnar (heptavalent pneumococcal conjugate vaccine): disease prevention in infants and children.
    Shields B
    J Pediatr Health Care; 2001; 15(4):203-8; quiz 209-10. PubMed ID: 11462129
    [No Abstract]   [Full Text] [Related]  

  • 6. Pneumococcal conjugate vaccine: economic issues of the introduction of a new childhood vaccine.
    Ray GT
    Expert Rev Vaccines; 2002 Jun; 1(1):65-74. PubMed ID: 12908513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modelling the costs and effects of a universal infant immunization program using conjugated pneumococcal vaccine in British Columbia.
    Moore D; Bigham M; Patrick D
    Can Commun Dis Rep; 2003 Jun; 29(11):97-104. PubMed ID: 12794969
    [No Abstract]   [Full Text] [Related]  

  • 8. An Advisory Committee Statement (ACS). National Advisory Committee on Immunization (NACI). Statement on recommended use of pneumococcal conjugate vaccine.
    National Advisory Committee on Immunization
    Can Commun Dis Rep; 2002 Jan; 28(ACS-2):1-32. PubMed ID: 12728645
    [No Abstract]   [Full Text] [Related]  

  • 9. Capsules, clones, and curious events: pneumococcus under fire from polysaccharide conjugate vaccine.
    Long SS
    Clin Infect Dis; 2005 Jul; 41(1):30-4. PubMed ID: 15937759
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of pneumococcal polysaccharide vaccine on nonbacteremic pneumococcal pneumonia.
    Weiser JN; Austrian R
    Clin Infect Dis; 2007 Apr; 44(8):1139-40; author reply 1140-1. PubMed ID: 17366469
    [No Abstract]   [Full Text] [Related]  

  • 11. Pediatric hospitalization for pneumococcal diseases preventable by 7-valent pneumococcal conjugate vaccine in Hong Kong.
    Ho PL; Chiu SS; Chow FK; Mak GC; Lau YL
    Vaccine; 2007 Sep; 25(39-40):6837-41. PubMed ID: 17714837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update on the recommendations for the routine use of pneumococcal conjugate vaccine for infants. An Advisory Committee Statement (ACS).
    National Advisory Committee on Immunization (NACI)
    Can Commun Dis Rep; 2006 May; 32(ACS-4):1-6. PubMed ID: 16718922
    [No Abstract]   [Full Text] [Related]  

  • 13. Promises and challenges of pneumococcal conjugate vaccines for the developing world.
    Grijalva CG; Edwards KM
    Clin Infect Dis; 2006 Sep; 43(6):680-2. PubMed ID: 16912938
    [No Abstract]   [Full Text] [Related]  

  • 14. [Pneumococcal disease and its prevention. The heptavalent pneumococcal conjugate vaccine].
    de Arístegui Fernández J; Corretger Rauet JM; García Martín F; Hernández-Sampelayo T; Moraga Llop FA; Rodrigo Gonzalo De Liria C; Ruiz Contreras J;
    An Esp Pediatr; 2002 Jan; 56(1):79-90. PubMed ID: 11792258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Two pneumococcal vaccines: the 7-valent conjugate vaccine (Prevenar) for children up to the age of 5 years and the 23-valent polysaccharide vaccine (Pneumo 23) for the elderly and specific groups at risk].
    de Greeff SC; Sanders EA; de Melker HE; van der Ende A; Vermeer PE; Schouls LM
    Ned Tijdschr Geneeskd; 2007 Jun; 151(26):1454-7. PubMed ID: 17633974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of abbreviated and delayed 7-valent pneumococcal conjugate vaccine dosing regimens.
    Mahon BE; Hsu K; Karumuri S; Kaplan SL; Mason EO; Pelton SI; ;
    Vaccine; 2006 Mar; 24(14):2514-20. PubMed ID: 16417951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progress in introduction of pneumococcal conjugate vaccine--worldwide, 2000-2008.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2008 Oct; 57(42):1148-51. PubMed ID: 18946462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pneumococcal vaccines for infants and children--past, present, and future.
    Klein JO
    Curr Clin Top Infect Dis; 2002; 22():252-65. PubMed ID: 12520657
    [No Abstract]   [Full Text] [Related]  

  • 19. Immunisation with a pneumococcal 7-valent conjugate vaccine.
    Dagan R
    Int J Clin Pract; 2002 May; 56(4):287-91. PubMed ID: 12074212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and effectiveness against respiratory tract infections for pneumococcal conjugate vaccine co-administered with routine vaccine combinations.
    Adam D; Fehnle K
    Vaccine; 2008 Nov; 26(47):5944-51. PubMed ID: 18801402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.